Dr. Jessica Kaplan Altman, MD

Dr. Altman practices at Northwestern Memorial Hospital in Chicago, Illinois, part of Northwestern Memorial HealthCare.

Dr. Altman's NPI, 1831391200, was assigned on June 5, 2007. Dr. Altman graduated from University of Pittsburgh School of Medicine in 2001. Dr. Altman holds Illinois license 036111034.

Dr. Altman's primary practice is Northwestern Memorial Hospital, at 251 E Huron St, Chicago, IL 60611 in Cook County. The practice phone is (312) 926-2000.

Dr. Altman's primary practice is Northwestern Memorial Hospital in Chicago, Illinois, part of Northwestern Memorial HealthCare. Dr. Altman is also affiliated with Northwestern Medicine Central DuPage Hospital. The medical group on file is Northwestern Medical Faculty Foundation. Dmand AI also links Dr. Altman to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Altman practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Altman's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Altman is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Altman's licenses on file in 2 states: Illinois and Florida.

Dmand AI lists chronic leukemia, lymphoma, multiple myeloma, prostate cancer and purpura and thrombocytopenia among the conditions Dr. Altman treats.

CMS data shows 17,475 Medicare services from Dr. Altman across 24 procedure codes in 2024, for 300 Medicare patients. Medicare paid $380,428 for them.

CMS counts 300 Medicare patients who saw Dr. Altman in 2024. The largest group is 65 to 74, with 143 patients. 73% of them have high blood pressure, and 69% have high cholesterol. 12% are also on Medicaid. Their average risk score is 2.95, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Altman's median patient age at 71, with 50% women.

In 2024, Dr. Altman wrote 293 Medicare Part D claims for 49 patients. 66% of them were for generic drugs. CMS names the drug for 145 of them, across 8 drugs with 11 or more claims each, at $469,066 in total drug cost. In 2023, CMS named 126 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Altman for performance year 2024, reported through an alternative payment model (APM). Dr. Altman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Altman as offering telehealth.

Dmand AI links 197 papers to Dr. Altman, published from 2007 to 2025. 2021 was the busiest year, with 12. The most frequent topics are Leukemia, Myeloid, Acute, Antineoplastic Agents and Antineoplastic Combined Chemotherapy Protocols. Dr. Altman has published most often in Blood. Dr. Altman's most frequent co-authors are Martin S. Tallman, MD, Francis J. Giles, MD and Daniel Aaron Pollyea, MD.

Dmand AI links Dr. Altman to 26 clinical trials, 7 of them phase 1 studies. 8 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Leukemia, Myeloid and Myelodysplastic Syndromes. ECOG-ACRIN Cancer Research Group sponsors the most, 4.

CMS Open Payments shows 137 general payments to Dr. Altman from 26 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 57% of the total. Daiichi Sankyo Inc. paid the most, $26,344. It also lists 48 research payments totaling $21,193 from 2017 to 2023.

Dmand AI lists 1 award for Dr. Altman, most recently CMS Stage 1 2012 in 2011.

Dr. Altman graduated from University of Pittsburgh School of Medicine in 2001. Dr. Altman is a member of ASCO and ASH.

Dr. Altman is in network with 16 carriers, including Aetna, Elevance and HCSC. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.